U.S. Biotech Stock News

Why AppFolio Stock Is Back on Investors’ Radar AppFolio (APPF) has quietly outperformed over the past week, adding about 5% and trimming some of its slide from the past 3 months, even as the 1-year return remains slightly negative. See our latest analysis for AppFolio. With the share price now around $236.21, AppFolio’s recent 7 day share price return of just over 5% is a welcome shift after a weaker 90 day patch. Its three year total shareholder return above 120% shows the longer term...

If you are wondering whether Electronic Arts at around $203 a share is still a smart buy or if the easy gains are behind it, this article walks through exactly what the current price might be baking in. The stock has slipped about 0.2% over the past week and is roughly flat over the last month, but it is still up about 39.7% year to date and 39.0% over the past year, hinting that sentiment has shifted meaningfully in its favor. That momentum has been underpinned by a steady pipeline of major...

Over the last month the MaxLinear, Inc. ( NASDAQ:MXL ) has been much stronger than before, rebounding by 33%. But that...

In recent weeks, MP Materials has seen insider share sales by its CEO and CFO, even as Morgan Stanley upgraded the company and institutional investors increased their holdings, underscoring its role in the rare earths supply chain. This mix of executive selling and institutional accumulation highlights differing views on MP Materials’ prospects, while reinforcing how important rare earth exposure has become for investors focused on critical materials security. We’ll now explore how Morgan...

Zenas BioPharma (ZBIO) is drawing fresh interest as investors position ahead of early January Phase 3 topline data for obexelimab in IgG4 related disease, a catalyst that could reshape expectations for the stock. See our latest analysis for Zenas BioPharma. The latest catalyst is landing on top of intense recent momentum, with a 1 day share price return of 17.1 percent, extending a 90 day share price return of 123.3 percent and a 1 year total shareholder return of 342.3 percent, as investors...

Johnson & Johnson (JNJ) has quietly climbed about 17% over the past 3 months and roughly 44% year to date, putting the spotlight back on what investors are really paying for its steady healthcare engine. See our latest analysis for Johnson & Johnson. The move has been fuelled by renewed confidence in its Innovative Medicine pipeline and steady MedTech demand, with the roughly 44% year to date share price return outpacing its already solid multi year total shareholder returns and signalling...

How Has Berkshire Hathaway Stock Been Performing? Berkshire Hathaway might look expensive at first glance given its share price, but the real question for long term investors is whether the underlying business is still trading for less than it is worth. Over the last few years, the share price has climbed steadily, delivering returns of 63.1% over 3 years and 118.9% over 5 years, even though the last month has been relatively flat with a 0.8% pullback and the last week down 1.3%. Recent...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

If you are wondering whether Marriott International is still attractively valued at current levels or if much of the potential upside may already be reflected in the share price, this breakdown is designed to help you cut through the noise and focus on value. The stock has climbed 1.7% over the last week, 6.1% over the past month, and is up 14.3% year to date, following gains of 117.6% and 153.5% over the last 3 and 5 years respectively. Those moves sit against a backdrop of ongoing travel...

Those holding Adeia Inc. ( NASDAQ:ADEA ) shares would be relieved that the share price has rebounded 38% in the last...

If you are wondering whether Rollins is still worth buying after its big run up, or if most of the upside is now priced in, you are not alone. This is exactly what we are going to unpack. The stock has climbed 1.9% over the last week, 1.4% over the past month, and is now up about 32.8% year to date and 33.0% over the last year, with longer term gains of 71.3% over 3 years and 67.7% over 5 years from a recent close of $61.14. Those returns come against a backdrop of steady demand for pest...

Opendoor Technologies (OPEN) just refreshed its leadership bench by naming fintech veteran Lucas Matheson as president and elevating long time insider Christy Schwartz to CFO, a move squarely aimed at accelerating the company’s Opendoor 2.0 pivot. See our latest analysis for Opendoor Technologies. The leadership reshuffle caps a wild year in which Opendoor’s 2025 share price return has jumped roughly 300 percent, even as more recent share price performance has cooled and momentum looks more...

Trupanion (TRUP) is back in the spotlight after a busy stretch, from a new distribution partnership with Pawp Insurance Solutions to CEO Margaret Tooth’s recent stock sale and option exercise following better than expected earnings. See our latest analysis for Trupanion. Those moves land against a mixed backdrop, with Trupanion’s share price now at $38.05, a solid 1 month share price return but a weaker 1 year total shareholder return suggesting momentum is rebuilding from a still bruised...

Carnival Corporation & plc recently reported record full-year 2025 results, with revenue rising to US$26.62 billion and net income reaching US$2.76 billion, and the board approved reinstating a quarterly dividend of US$0.15 per share starting with a February 27, 2026 payment. The company also proposed unifying its dual-listed structure into a single Bermuda-incorporated entity listed on the NYSE, aiming to simplify governance, cut administrative costs, and potentially improve share liquidity...

Iovance Biotherapeutics recently strengthened its position by granting inducement stock options to new employees while benefiting from fresh analyst coverage and renewed optimism toward its Amtagvi cell therapy and broader pipeline. This combination of talent incentives and improving sentiment around tumor-infiltrating lymphocyte therapies, including potential expansion into non-small cell lung cancer, is reframing how investors view the company’s long-term prospects. We’ll now explore how...

D-Wave Quantum recently announced plans to showcase its Advantage2 annealing quantum system and real-world customer use cases at CES 2026, highlighting growing commercial traction, expanding government initiatives, and fresh institutional interest. This combination of product availability, expanding use cases across industries, and bullish analyst coverage is reshaping how investors view the company’s commercialization timeline and competitive positioning in quantum computing. With D-Wave’s...

Compañía de Minas Buenaventura S.A.A. ( NYSE:BVN ) shares have continued their recent momentum with a 26% gain in the...

Grabar Law Office has launched an investigation into Molina Healthcare (MOH), questioning whether management adequately disclosed rising medical cost trends and a mismatch between premiums and underlying costs, which has put the company’s 2025 financial guidance under sharper investor scrutiny. See our latest analysis for Molina Healthcare. The investigation is landing after a volatile stretch, with Molina’s share price at $163.68 following a strong 1 month share price return, but a steep...

If you are wondering whether Halozyme Therapeutics at around $68 is still a smart buy, or if most of the upside is already priced in, you are not alone. This article is going to tackle that value question head on. The stock is up 7.4% over the last week and 42.0% year to date, even after a slightly softer 30 day patch with a 3.1% pullback, adding up to a 44.5% gain over the past year. Recent gains have largely been driven by growing investor confidence in Halozyme Therapeutics drug delivery...

Cognizant recently announced a series of multi-year agreements, including an AI-focused partnership with Microsoft, new AI-driven BPaaS and IT modernization deals with Bupa Hong Kong, ERIKS, and BayWa, alongside the opening of an India AI Lab and Cognizant Moment Studio in Bengaluru to deepen applied AI research and innovation. Together, these moves highlight how Cognizant is integrating agentic AI and sector-specific platforms into core client workflows, aiming to reposition itself as an...

Venture Global (VG) has quietly turned into a roller coaster for investors, with the stock jumping 4% in a day but still sitting deeply red over the past 3 months and year to date. See our latest analysis for Venture Global. That sharp 1 day and 7 day share price return rebound comes after months of heavy selling, with the 90 day and year to date share price returns still pointing to fading momentum as investors reassess both growth prospects and risk. Given how quickly sentiment can swing in...

Wondering if STAAR Surgical at around $24 a share is a hidden bargain or a value trap? You are not alone, and that is exactly what we are going to unpack. The stock has been choppy, up 2.7% over the last week but down 13.6% over the past month. Despite being barely positive year to date at 0.4%, it is still sitting on steep losses of around 50% over three years and 70% over five. Those big swings are set against a backdrop of ongoing excitement around implantable Collamer lenses and the...

SEALSQ’s recently announced partnership with Airmod delivered a production-ready, open-source-enabled middleware stack built on SEALSQ Secure DevKits to speed deployment of quantum-resistant IoT devices, alongside appointing industry veteran Rolf Gobet to lead its Geneva Quantum Center of Excellence within the Europe-focused Quantum Corridor initiative. Together, the Airmod collaboration and Gobet’s leadership role highlight SEALSQ’s push to offer end-to-end post-quantum cybersecurity...

Key Insights The projected fair value for DXP Enterprises is US$171 based on 2 Stage Free Cash Flow to Equity DXP...